Clinical Trials Browser

Ototoxicity × sodium thiosulfate × Clear all

Ototoxicity, Neoplasms, Germ Cell and Embryonal, Hepatoblastoma

NCT00716976 2023-11-09

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Ovarian Germ Cell Cancer, Ototoxicity, Brain Neoplasms, Liver Neoplasms, Medulloblastoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Central Nervous System Neoplasms, Hepatoblastoma

NCT04262336 2023-07-06

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

Phase 1 Completed

22 enrolled

Ototoxicity, Hearing Loss

NCT00652132 2018-05-29

SIOPEL6

Phase 3 Completed

116 enrolled 1 FDA

Gastrointestinal

Ototoxicity, Liver Neoplasms, Hepatoblastoma

Clinical Trials

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment

SIOPEL6